Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M
August 08 2022 - 6:00AM
Bionomics Limited (ASX: BNO, NASDAQ:BNOX), a clinical stage
biopharmaceutical company, is pleased to announce that the Company
has received A$2,085,453.17 research and development (R&D) tax
incentive refund relating to the financial year ended June 2021.
The Australian Government R&D tax incentive encourages
companies to engage in R&D benefiting Australia, by providing a
tax offset of up to 43.5% (refundable) for eligible R&D
activities.
Released on authority of the Executive Chairman.
FOR FURTHER INFORMATION PLEASE CONTACT:
General:Ms Suzanne IrwinCompany Secretary+61 8
8150 7400CoSec@bionomics.com.au |
Investor Relations:Mr. Connor BernsteinVice
President, Strategy and Corporate Development+1 (650)
524-5143cbernstein@bionomics.com.au |
About Bionomics LimitedBionomics (ASX:BNO,
NASDAQ:BNOX) is a clinical-stage biopharmaceutical company
developing novel, allosteric ion channel modulators designed to
transform the lives of patients suffering from serious central
nervous system (CNS) disorders with high unmet medical need.
Bionomics is advancing its lead drug candidate, BNC210, an oral,
proprietary, selective negative allosteric modulator of the α7
nicotinic acetylcholine receptor, for the acute treatment of Social
Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic
Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic
partnership with Merck & Co., Inc (known as MSD outside the
United States and Canada) with two drugs in early-stage clinical
trials for the treatment of cognitive deficits in Alzheimer’s
disease and other central nervous system conditions.
www.bionomics.com.au
Bionomics (NASDAQ:BNOX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Bionomics (NASDAQ:BNOX)
Historical Stock Chart
From Dec 2023 to Dec 2024